Thalocan Research Innovations has partnered with Arash Mostaghimi, MD, MPA, MPH to develop a comprehensive training for the BETA and BELA to accompany The Severity of Alopecia Tool (SALT), training for a robust and high quality Alopecia assessment curriculum. Our mission is to support clinical raters with a clear understanding of the scoring criteria for…
DetailsThe fourth in our series of Conversations with Portia Combow and living with HS. Thalocan Research Innovations CEO Eric Zudak and Portia discuss the roadblocks she’s encountered with clinical studies. Watch the full webinar/conversation at www.thalocan.com/webinars/.
Thanks to Dr. Amit Garg for his kind words about his experience with Thalocan Research Innovations specifically the development of LAMA – Thalocan’s Lesion Area Mapping assistant. This state-of-the-art tool would not be possible without the invaluable consult and input from Dr. Garg, as well as Professor John Ingram. We’re grateful for their assistance in…
DetailsTRI shares just one of the features of Thalocan’s Lesion Area Mapping Assistant (LAMA) – revolutionizing clinical assessment of HS, among other indications. Learn more at: https://www.thalocan.com/lama/
The fourth in our series of Conversations with Portia Combow and living with HS. Thalocan Research Innovations CEO Eric Zudak and Portia discuss the roadblocks she’s encountered with clinical studies. Watch the full webinar/conversation at www.thalocan.com/webinars/.
Why We Built Thalocan: The Forgotten Links in Dermatology Clinical Trials Interview with Eric Zudak, CEO of Thalocan Research Innovations by Ginger Claremohr, Claremohr Writing Co. There’s a moment in every startup story when frustration turns into fuel. For Eric Zudak, founder of Thalocan Research Innovations, that moment came when a global pharmaceutical company called…
DetailsOld school paper record keeping is time-consuming with a higher potential for missteps. Avoiding this is just ONE of the many reasons we designed LAMA. A patent-pending, BYOD cloud-based solution, Thalocan’s Lesion Area Mapping Assistant (LAMA) is built on a single concept: improve lesion assessment during dermatologic clinical trials with a streamlined, comprehensive and structured…
DetailsTeresa DeHaemer, our Senior Director of Business Strategy shares just a small part of her experience at hashtag#RAD2025 – The Revolutionizing Atopic Dermatitis conference in Nashville, which took place June 6th and 7th. Joined by Tyler White, our Senior Director of Business Development, Thalocan Research Innovations expresses our sincere thanks for all the insight, presentations,…
DetailsThe third installment in our series, Conversations with Portia Combow: After being incorrectly diagnosed, first with a staph infection and then with folliculitis – Portia discusses her experience and the treatment options she pursued prior to getting correctly diagnosed with Hidradenitis Suppurativa. Watch the full webinar/conversation at www.thalocan.com/webinars/.
“How long did it take to get your diagnosis?” is the next topic in our series, Living with HS – conversations with Portia Combow. As Thalocan continues to work to improve the process of disease assessment in clinical research, we are grateful to Portia as she shares her unique and first-hand experience with Hidradenitis Suppurativa.…
Details
